Two ctDNA assays have been approved for clinical use by the United States Food and Drug Administration (FDA) and the European Medicines Agency for patients with NSCLC who are not eligible for a tissue biopsy or have an acquired resistance to EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.